(Q43706439)

26 November 2017

Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations (English)

1 reference

26 November 2017

2

1 reference

26 November 2017

O V Olesen

1

1 reference

26 November 2017

1 August 2001

1 reference

The Journal of Clinical Pharmacology

26 November 2017

1 reference

26 November 2017

41

1 reference

26 November 2017

8

1 reference

26 November 2017

823-832

1 reference

Clozapine. A novel antipsychotic agent

26 November 2017

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010717

Pharmacokinetics and pharmacodynamics of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010717

Clozapine-induced agranulocytosis. Incidence and risk factors in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010717

Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010717

Single- vs multiple-dose pharmacokinetics of clozapine in psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010717

The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010717

Characterization of the human hepatic cytochromes P450 involved in the in vitro oxidation of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010717

Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010717

Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010717

Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010717

Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010717

Influence of patient-related variables on clozapine plasma levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010717

Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010717

Effect of caffeine on clozapine pharmacokinetics in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010717

Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010717

Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010717

Merits and limitations of recombinant models for the study of human P450-mediated drug metabolism and toxicity: an intralaboratory comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010717

Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010717

10.1177/00912700122010717

21 January 2018

Identifiers

DOI

1 reference

26 November 2017

1 reference

PubMed ID

11504269